



**Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting  
March 4, 2009**

**Location: Learning Resource Center  
3550 Mills Civic Parkway  
West Des Moines, Iowa**

**Time: 9:30 a.m. – 1:30 p.m.**

**Final Agenda**

1. Welcome & Introductions
  - a) Commission Members and Staff
  - b) Approval of the minutes
  - c) Old business
2. Iowa Medicaid Enterprise Update(s)
  - a) February 20<sup>th</sup> Clinical Advisory Committee Report
  - b) Other IME/DHS Updates
3. P&T Committee's Recommendations on Select Mental Health Drugs – Report from February 13<sup>th</sup> Mental Health Advisory Group meeting
4. Prior Authorization
  - a) Extended Release Formulations Prior Authorization Criteria
  - b) Modified Formulations Prior Authorization Criteria
5. Public Comment (See Conflict of Interest Disclosure Form)
6. ProDUR Edits: *Quantity Limits List*: acetaminophen-containing analgesics
7. Focus Studies/Provider Education Initiatives
  - a) New Clozapine Users and Frequency of Monitoring – Follow up
  - b) Concurrent Inhaled Anticholinergics – Initial Review
  - c) Protease Inhibitors with HMG CoA Inhibitors – Initial Review
  - d) Thiazolidinediones in Congestive Heart Failure – Initial Review
  - e) Use of Metered Dose Inhalers vs. Nebulizers – Initial Review
8. Public Comment

9. Miscellaneous

- a) DUR Digest (Draft) 2009 Volume 21, Number 2
- b) MedWatch

10. Executive Closed Session

- a) Approval of Minutes
- b) Review of Focus Studies Data with PHI
- c) Member Profiles

11. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information contact the DUR Director, Chad Bissell, Pharm.D. at [info@iadur.org](mailto:info@iadur.org) or (515) 725-1271